Cargando…

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study

OBJECTIVE: To identify clusters of peripheral involvement according to the specific location of peripheral manifestations (ie, arthritis, enthesitis and dactylitis) in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), and to evaluate whether these clusters correspond with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Medina, Clementina, Chevret, Sylvie, Molto, Anna, Sieper, Joachim, Duruöz, Tuncay, Kiltz, Uta, Elzorkany, Bassel, Hajjaj-Hassouni, Najia, Burgos-Vargas, Ruben, Maldonado-Cocco, José, Ziade, Nelly, Gavali, Meghna, Navarro-Compan, Victoria, Luo, Shue-Fen, Biglia, Alessandro, Tae-Jong, Kim, Kishimoto, Mitsumasa, Pimentel-Santos, Fernando M, Gu, Jieruo, Muntean, Laura, van Gaalen, Floris A, Geher, Pál, Magrey, Marina, Ibáñez-Vodnizza, Sebastián E, Bautista-Molano, Wilson, Maksymowych, Walter, Machado, Pedro M, Landewé, Robert, van der Heijde, Desirée, Dougados, Maxime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576480/ https://www.ncbi.nlm.nih.gov/pubmed/34750246 http://dx.doi.org/10.1136/rmdopen-2021-001728

Ejemplares similares

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study
por: López-Medina, Clementina, et al.
Publicado: (2021)

Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study
por: Benavent, Diego, et al.
Publicado: (2022)

Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study
por: Chaudhary, Haseeb, et al.
Publicado: (2023)

Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
por: Boel, Anne, et al.
Publicado: (2022)

Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study
por: Arevalo Salaet, Marta, et al.
Publicado: (2022)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
por: Sieper, Joachim, et al.
Publicado: (2019)

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages
por: Kiltz, U, et al.
Publicado: (2016)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort
por: Pons, Marion, et al.
Publicado: (2022)

Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five‐Year Data From the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
por: Madari, Queeny, et al.
Publicado: (2020)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Determinants of the Physician Global Assessment of Disease Activity and Influence of Contextual Factors in Early Axial Spondyloarthritis
por: Hirano, Fumio, et al.
Publicado: (2022)

Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2022)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
por: Navarro-Compán, Victoria, et al.
Publicado: (2022)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Is there a relationship between spondyloarthritis and periodontitis? A case–control study
por: Bautista-Molano, Wilson, et al.
Publicado: (2017)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2022)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
por: Deodhar, Atul, et al.
Publicado: (2021)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Evaluation of the performances of ‘typical’ imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study
por: Molto, Anna, et al.
Publicado: (2019)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‐Year Results From the DESIR Cohort
por: Ramiro, Sofia, et al.
Publicado: (2019)

Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity
por: van Genderen, Simon, et al.
Publicado: (2016)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
por: Molto, Anna, et al.
Publicado: (2021)

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?
por: Bakker, P. A. C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nksofhth77n0lpo19rvn2kr7of